Social pacts, employment and growth: a reappraisal of Ezio Tarantellis thought. Heidelberg: Springer Verlag. ISBN 978-3-7908-1915-1. Anderson, Elizabeth (2017). Private Government: How Employers Rule Our Lives (and Why We Dont Talk about It). Princeton, NJ: Princeton University Press. ISBN 978-0-691-17651-2. Dubin, Robert (1958). The World of Work: Industrial Society and Human Relations. Englewood Cliffs, N.J: Prentice-Hall. p. 213. OCLC 964691. Freeman, Richard B.; Goroff, Daniel L. (2009). Science and Engineering Careers in the United States: An Analysis of Markets and Employment. Chicago: University of Chicago Press. ISBN 978-0-226-26189-8. Lee, Eddy (January 1996). "Globalization and Employment: Is Anxiety Justified?". International Labour Review. 135 (5): 485–98. Archived from the original on 2013-05-16. Retrieved 2017-08-27. Markey, Raymond; Hodgkinson, Ann; Kowalczyk, Jo (2002). "Gender, part-time employment and employee participation in Australian workplaces". Employee Relations. 24 (2): 129–50. doi:10.1108/01425450210420884. Stone, Raymond J. (2005). Human Resource Management (5th ed.). Milton, Qld: John Wiley. pp. 412–14. ISBN 978-0-470-80403-2. Wood, Jack M. (2004). Organisational Behaviour: A Global Perspective (3rd ed.). Milton, Qld: Wiley. pp. 355–57. ISBN 978-0-470-80262-5. External links

Business Link (archived from the original on 29 September 2012)
"Labor and Employment". Government Information Library. University of Colorado at Boulder. Archived from the original on 2009-06-12. Retrieved 2009-08-05. "Overview and topics of labour statistics". Statistics and databases. International Labour Organization.
Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved for human use. It is marketed as an ointment under the brand names Altabax and Altargo. Retapamulin was approved by the United States Food and Drug Administration in April 2007 for the treatment of bacterial skin infections such as impetigo. In May 2007, retapamulin received approval in the EU from the European Medicines Agency for the same indication. Clinical trials have demonstrated its efficacy against certain Gram-positive bacteria including MRSA. Indications
Retapamulin is indicated for the topical treatment of impetigo due to Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes. Pharmacology
Mechanism of action
Retapamulin is an antibacterial agent, specifically a protein synthesis inhibitor. The medication selectively inhibits bacterial protein synthesis by interacting at a site on the 50S subunit of the bacterial ribosome through an interaction that differs from other antibiotics. Pharmacokinetics
Systemic exposure following topical application through intact skin is low. Contraindications
None yet reported. Adverse reactions
The most common reported adverse reaction was irritation at the application site. == References ==